Pulmonary arterial hypertension (PAH) is a challenging disease to diagnose accurately as it requires invasive investigations and significant experience to manage patients effectively. Pulmonary arterial hypertension is a progressive disorder, characterized by high blood pressure in pulmonary arteries, which carry blood from the heart to the lungs. PAH is a very rare condition that occurs when pulmonary arteries become narrow in diameter or get blocked. However, there are treatments available in the market that can help patients manage the symptoms of PAH. Prostacyclin and prostacyclin analogs, endothelin receptor antagonists (ERAs), phosphodiesterase-5 (PDE-5), and soluble guanylate cyclase (sGC) stimulators are the major classes of drugs that are used to manage PAH symptoms. The PAH treatment may include pills such as ambrisentan (Letairis), bocentan (Tracleer), macitentan (Opsumit), riocigaut (Adempas), selexipag (Uptravi), sildenafil (Revatio), tadalafil (Adcirca), treprostinil (Orenitram); inhalers such as Iloprost tromethamine (Ventavis), treprostinil (Tyvaso); and intravenous drugs such as epopostenol sodium (Flolan, Veletri), treprostinil.
The global pulmonary arterial hypertension market report estimates the market size (Revenue US$ million – 2014 to 2021) for key market segments based on the drug classes (endothelin receptor antagonists, phosphodiesterase-5 inhibitors, prostacyclin and prostacyclin analogs, and soluble guanylate cyclase stimulators), pipeline analysis of clinical 1, 2, and 3 drugs, and forecasts growth trends (CAGR% – 2017 to 2021).
The global pulmonary arterial hypertension market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global pulmonary arterial hypertension market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Major players operating in the global pulmonary arterial hypertension market and included in this report are Actelion Pharmaceuticals, Ltd., Bayer HealthCare, Gilead Sciences, Inc., GlaxoSmithKline plc, Novartis International AG, Pfizer, Inc., and United Therapeutics Corporation.